SEARL enters into an exclusive licensing & marketing agreement of Remdesivir with Beximco Pharmaceuticals

May 29, 2020 (MLN): The Searle Company Limited has successfully entered into an exclusive licensing & marketing agreement with Beximco Pharmaceuticals, Bangladesh.

Beximco is the first company in the world who developed and introduced generic of Remdesivir for the treatment of Covid-19.

Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. Remdesivir is administered intravenously and is authorized for the treatment of hospitalized patients with severe COVID-19 disease. 

Remdesivir has been granted emergency use authorization (EUA) by the U.S. Food & drug Administration (FDA) & authorities in Japan to treat hospitalized patients with severe Covid-19.

This partnership will provide an immediate supply of the finished product at an affordable price and will help health care providers of Pakistan to treat their hospitalized Covid-19 patients without any delay.

Initially, the company is planning to import Remdesivir in finished form (ready to use) to meet the country's urgent requirements.

 The company is also planning to donate a sizeable quantity to the Government of Pakistan which is actively fighting against this pandemic.

Copyright Mettis Link News